2023 TCT Healthcare Application Award

Winner: Triastek
Partners: Eli Lilly; Merck KgA; Siemens

Working with partners Eli Lilly, Merck KgA and Siemens, Triastek has developed Melt-Extrusion Deposition (MED®), a pharmaceutical 3D printing technology which ensures more effective drug delivery, controlling when, where and how much API is released. Thought to be the world’s first continuous manufacturing line for 3D printing pharmaceuticals, MED has a production rate of approximately 50 million tablets per year.